Navigation Links
Regulatory Path for Bronchitol in Bronchiectasis
Date:5/1/2008

SYDNEY, Australia, May 1 /Xinhua-PRNewswire-FirstCall/ -- Pharmaxis (AXS: PSX; Nasdaq: PXSL) today announced that it has agreed with advice from the U.S. Food and Drug Administration (FDA) on the design of a pivotal Phase 3 trial of the company's mucus clearing agent, Bronchitol, in patients with bronchiectasis.

The trial is a randomized, double-blind investigation of Bronchitol twice daily in approximately 300 adults with bronchiectasis. Participants will be treated for 52 weeks during which they will be assessed for reduction in frequency of exacerbations and quality of life. The trial will be undertaken in Europe and the USA.

This trial is the second Phase III study to be undertaken with Bronchitol in people with bronchiectasis and follows the completion of a successful trial reported during the third quarter of 2007. These trials are expected to form the basis of a marketing application in both the European Union and the U.S. Recruitment of volunteers will begin following receipt of the necessary approvals to begin the trial and is expected to be during the third quarter of 2008.

The clinical trial protocol requires final review by both the U.S. FDA under their Special Protocol Assessment (SPA) process and the European Medicines Agency, the EMEA.

The SPA process allows for FDA evaluation of a clinical trial protocol intended to form the primary basis of an efficacy claim in support of a New Drug Application, and provides an agreement that the study design, including trial size, clinical endpoints and/or data analyses are acceptable to the FDA.

Alan Robertson (Pharmaxis CEO) said, "To ensure that this pivotal trial can start quickly and be completed efficiently, Pharmaxis has assembled a specific advisory board of opinion leading physicians in bronchiectasis and employed clinical and regulatory staff in the US and EU. There are no products specifically approved for bronchiectasis and Bronchitol remains the only product cu
'/>"/>

SOURCE Pharmaxis Ltd
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Dr. Audrey F. Jakubowski of SuperGen Retires as Chief Regulatory and Quality Officer
2. FDA and Conformia Deliver Joint Presentation to Annual Regulatory and Compliance Symposium at Harvard
3. Thomson Scientific to Host Pharmaceutical Vision - A Users Conference for Information, Regulatory Affairs, Competitive Intelligence and Biotechnology Professionals
4. Cadence Pharmaceuticals Names Malvina Laudicina Vice President of Regulatory Affairs and Quality Assurance
5. Velcura Therapeutics, Inc. Appoints Industry Executive to Lead Regulatory Affairs
6. Wyeth Provides Update on Regulatory Review of Viviant (bazedoxifene)
7. Pearl Therapeutics, Inc. Expands Its Senior Management Team With Top Talent in Clinical Development and Regulatory Affairs
8. ExonHit Gets Regulatory Approval to Initiate a Phase 2 Clinical Trial for EHT 0202 in Alzheimers Disease
9. Kendle Appoints Former MHRA Head of Biologics as Principal Regulatory Affairs Consultant
10. Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain
11. Cephalon Provides Update on Regulatory Status of the FENTORA Supplemental New Drug Application
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... form and develop on platinum nanocubes point the ... and reveal that a nearly 150 year-old scientific ... nanoscale. , Researchers with the U.S. Department of ... used highly sophisticated transmission electron microscopes and an ... mechanisms that control the evolution of facets ...
(Date:8/22/2014)... 22, 2014 Ophthalmic drug delivery ... and challenging endeavors as the anatomy, physiology and ... to the foreign substances. Ocular drug delivery technologies ... medication and minimal use of needles; also it ... and provides specific targeting within the ocular globe. ...
(Date:8/22/2014)... Aug. 22, 2014 Research and Markets ... and China Gel Permeation Chromatography (GPC) Industry Report 2014" ... Global and China Gel Permeation Chromatography (GPC) Industry Report ... state of the global gel permeation chromatography industry with ... provides a basic overview of the industry including definitions, ...
(Date:8/22/2014)... August 22, 2014 The AMA is ... its members in Alaska that Alaska Governor Sean Parnell ... 15, further defining public use of Unmanned Aircraft Systems ... Force. House Bill 255states that it is, “An Act ... captured by an unmanned aircraft system.” It defines State ...
Breaking Biology Technology:Shaping the future of nanocrystals 2Shaping the future of nanocrystals 3Shaping the future of nanocrystals 4Ocular Drug Delivery Technologies Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Ocular Drug Delivery Technologies Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3Ocular Drug Delivery Technologies Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 4Global and China Gel Permeation Chromatography (GPC) Industry Report 2014 2State of Alaska Signs Unmanned Aircraft Systems Bill 2
... FRANCISCO, Calif., Aug. 7 Anesiva,Inc. (Nasdaq: ANSV ... quarter and six months ended June 30, 2008., ... Anesiva as we,introduced Zingo(TM) in the U.S. pediatric hospital ... "In addition, I,m pleased,to report that our Phase 3 ...
... Inc.,(Nasdaq: ITMN ) today announced that Daniel G. ... the Canaccord Adams 28th Annual,Global Growth Conference in Boston ... To access a live audio webcast of the presentation, ... investor relations page of InterMune,s,corporate website at http://www.intermune.com ...
... 7 Medicsight PLC, a subsidiary,of MGT Capital ... industry leader in the,development of Computer-Aided Detection (CAD) ... received approval from the Brazilian regulatory,agency, Agencia Nacional ... David Sumner, Chief Executive of Medicsight, commented: "This ...
Cached Biology Technology:Anesiva Announces Second Quarter 2008 Financial Results and Update 2Anesiva Announces Second Quarter 2008 Financial Results and Update 3Anesiva Announces Second Quarter 2008 Financial Results and Update 4Anesiva Announces Second Quarter 2008 Financial Results and Update 5Anesiva Announces Second Quarter 2008 Financial Results and Update 6Anesiva Announces Second Quarter 2008 Financial Results and Update 7Anesiva Announces Second Quarter 2008 Financial Results and Update 8Medicsight Receives Brazilian State Food and Drug Administration Approval for ColonCAD Software 2Medicsight Receives Brazilian State Food and Drug Administration Approval for ColonCAD Software 3
(Date:8/22/2014)... basic and clinical research and technological advances, the ... offensive spanning multiple fronts. , Work happening in ... find new and more selective therapies for cancer. ... specific enzyme overexpressed in certain cancersand they have ... , Chemistry professor Christopher Cairo and his team ...
(Date:8/22/2014)... American consumers will finally be able to purchase fuel ... as zero-emissions vehicles, most of the cars will run ... that contributes to global warming. , Now scientists at ... uses an ordinary AAA battery to produce hydrogen by ... through two electrodes that split liquid water into hydrogen ...
(Date:8/21/2014)... Nxt-ID, Inc. (OTCQB: NXTD), a biometric authentication ... today that its shares of common stock and the ... its proposed underwritten public offering of common stock and ... Capital Market, subject to closing of its proposed underwritten ... will trade under the symbol "NXTD" and "NXTDW," respectively. ...
Breaking Biology News(10 mins):New enzyme targets for selective cancer therapies 2New enzyme targets for selective cancer therapies 3Stanford scientists develop a water splitter that runs on an ordinary AAA battery 2Stanford scientists develop a water splitter that runs on an ordinary AAA battery 3Nxt-ID Approved for NASDAQ Capital Market Listing 2Nxt-ID Approved for NASDAQ Capital Market Listing 3
... warming in alpine regions is putting pressure on a rare ... released in Climatic Change Letters . In ... of Montana, U.S. Fish and Wildlife Service and National Park ... warning indicators of climate warming in mountain ecosystems. The glaciers ...
... Coastal mangrove forests store more carbon than almost any ... by a team of U.S. Forest Service and university ... Nature Geoscience . ( www.nature.com/naturegeoscience.com ) A ... and Northern research stations, University of Helsinki and the ...
... (April 4, 2011) An international team of researchers ... alcohol consumption, according to a new study published online ... of the National Academy of Sciences . ... that influence alcohol drinking behavior. Study contributors Danielle ...
Cached Biology News:Mangroves among the most carbon-rich forests in the tropics 2Gene involved in predisposition to alcohol consumption identified 2
... • Small design specifically for western blots ... are specifically designed for staining western blots. ... 25 mm) of the disposable tray requires ... significant cost savings to the user. Pour ...
... pLivSelect is a direct ... recombinant identification. Recombinant selection ... survival, eliminating the need ... This quick and inexpensive ...
... Signal Enhancer does for enzyme-/substrate-based blotting what intensifying ... the signal up to 10-fold (or one order ... Western Blot Signal Enhancer membrane treatment is a ... to your current Western blotting protocol. The result ...
... through columns is a well-known separation technique ... applications are in DNA/RNA extraction in microbiology, ... purification in chemical or analytical laboratories. ... Genesis series instruments for smaller scales. The ...
Biology Products: